Xu, Wenxin http://orcid.org/0000-0002-8450-2037
Atkins, Michael B.
McDermott, David F. http://orcid.org/0000-0002-2675-5095
Article History
Accepted: 9 January 2020
First Online: 4 February 2020
Competing interests
: M.B.A. serves on the advisory boards of Bristol-Myers Squibb (BMS), Merck, Novartis, Arrowhead, Pfizer, Galactone, Werewolf and Fathom. He serves as a consultant to BMS, Merck, Novartis, Pfizer, Genentech-Roche, Exelixis, Eisai, Aveo, Array, Ideera, Aduro, ImmunoCore, Boehringer-Ingelheim, Iovance, Newlink, Surface, Alexion, Acceleron, Pyxis, Cota and Amgen. He receives research support from BMS (to his institution) and owns stock options in Werewolf and Pyxis. D.F.M. receives consulting honoraria from BMS, Pfizer, Merck, Novartis, Exelixis, Array BioPharm, Genentech, Alkermes, Jounce Therapeutics, X4 Pharmaceuticals, Peloton, EMD Serono and Eli Lilly. He receives research support from BMS, Prometheus Laboratories, Merck, Genentech, Pfizer, Exelixis, Novartis, X4 Pharmaceuticals, Alkermes and Peloton. W.X. declares no competing interests.